Received Apr 9, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MENB | MENINGOCOCCAL B (BEXSERO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | — | — |
first dose at age 10 and second dose at age 16; This non-serious case was reported by a consumer via sales rep and described the occurrence of drug dose administration interval too long in a patient who received Men B NVS (Bexsero) for prophylaxis. Previously administered products included Bexsero (received 1st dose at the age 10). On an unknown date, the patient received the 2nd dose of Bexsero. On an unknown date, an unknown time after receiving Bexsero, the patient experienced drug dose administration interval too long (Verbatim: first dose at age 10 and second dose at age 16). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 25-MAR-2025 The doctor enquired if she needs to continue a possible 3rd dose of Bexsero vaccine if the adolescent received first dose at age 10 and second dose at age 16. The patient did not received second dose of vaccine within the recommended timeframe which led to drug dose administration interval too long. The case was raised for the apparent deviation of the recommended schedule, but no more data available.